Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Entinostat + Pembrolizumab in Non-Inflamed Metastatic Melanoma
NCT03765229Phase 2Completed
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Mar 2019
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of entinostat in melanoma, sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Number of Conversions of Non-inflamed to Inflamed Melanoma at 3 weeks. Started Mar 2019; status: completed.
02
Drugs
entinostat
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03765229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03765229.